John S Tokarski from 11 Walker Dr, Princeton, NJ 08540, age 65, Phone: 609-683-5858

Cannabinoid Receptor Modulators, Their Processes Of Preparation, And Use Of Cannabinoid Receptor Modulators For Treating Respiratory And Non-Respiratory Diseases
view source
US Patent:

6653304, Nov 25, 2003
Filed:

Feb 8, 2001
Appl. No.:

09/779109
Inventors:

Katerina Leftheris - Skillman NJ
Hong Wu - Lawrenceville NJ
Stephen Wrobleski - Whitehouse Station NJ
Ping Chen - Belle Mead NJ
John Hynes - Washington Crossing PA
John Tokarski - Princeton NJ
Assignee:

Bristol-Myers Squibb Co. - Princeton NJ
International Classification:

C07D40312
US Classification:

5142328, 514292, 544126, 546 81
Abstract:

Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R -R are as defined in the specification, wherein R with R may form a ring, and/or two R groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R forming a ring with R.

Crystallographic Structure Of The Androgen Receptor Ligand Binding Domain
view source
US Patent:

6795776, Sep 21, 2004
Filed:

Oct 13, 2000
Appl. No.:

09/687609
Inventors:

Roberto Weinmann - Lawrenceville NJ
Howard M. Einspahr - Lawrenceville NJ
Stanley R. Krystek - Ringoes NJ
John S. Sack - Lawrenceville NJ
Mark E. Salvati - Lawrenceville NJ
John S. Tokarski - Princeton NJ
Ricardo M. Attar - Lawrenceville NJ
Chihuei Wang - Plainsboro NJ
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

G01N 3100
US Classification:

702 27, 530350, 530399, 552621
Abstract:

The first crystal structure of the androgen receptor ligand binding domain has been determined to 2. 0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.

Heterocyclic Inhibitors Of Kinases
view source
US Patent:

7084160, Aug 1, 2006
Filed:

Jun 18, 2003
Appl. No.:

10/464139
Inventors:

Robert M. Borzilleri - New Hope PA, US
Rajeev S. Bhide - Princeton Jct NJ, US
John S. Tokarski - Princeton NJ, US
Peter Zheng - Lawrenceville NJ, US
Ligang Qian - Hopewell NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 31/44
C07D 417/12
US Classification:

514342, 5462681, 5462697, 5462707
Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Pyrrolotriazine Compounds As Kinase Inhibitors
view source
US Patent:

7141571, Nov 28, 2006
Filed:

Dec 22, 2004
Appl. No.:

11/019901
Inventors:

Brian E. Fink - Princeton Junction NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Ping Chen - Belle Mead NJ, US
Harold Mastalerz - Guilford CT, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Yufen Zhao - Pennington NJ, US
Wen-Ching Han - Newton PA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07D 487/04
A61K 31/53
US Classification:

514243, 544183
Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Crystallographic Structure Of The Androgen Receptor Ligand Binding Domain
view source
US Patent:

7225083, May 29, 2007
Filed:

Jun 28, 2004
Appl. No.:

10/878851
Inventors:

Roberto Weinmann - Lawrenceville NJ, US
Howard M. Einspahr - Lawrenceville NJ, US
Stanley R. Krystek - Ringoes NJ, US
John S. Sack - Lawrenceville NJ, US
Mark E. Salvati - Lawrenceville NJ, US
John S. Tokarski - Princeton NJ, US
Ricardo M. Attar - Lawrenceville NJ, US
Chihuei Wang - Plainsboro NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

G01N 31/00
G06F 19/00
C07K 1/00
C07J 1/00
A61K 38/22
US Classification:

702 27, 530350, 530399, 552621
Abstract:

The first crystal structure of the androgen receptor ligand binding domain has been determined to 2. 0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.

Pyrrolotriazine Compounds As Kinase Inhibitors
view source
US Patent:

7297695, Nov 20, 2007
Filed:

Jun 26, 2006
Appl. No.:

11/426479
Inventors:

Brian E. Fink - Princeton Junction NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Ping Chen - Belle Mead NJ, US
Harold Mastalerz - Guilford CT, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Yufen Zhao - Pennington NJ, US
Wen-Ching Han - Newtown PA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07D 487/04
C07D 401/06
C07D 401/14
A61K 31/53
A61P 35/00
US Classification:

514243, 544183
Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Fused Heterotricyclic Compounds As Inhibitors Of 17Β-Hydroxysteroid Dehydrogenase 3
view source
US Patent:

7378426, May 27, 2008
Filed:

Feb 25, 2005
Appl. No.:

11/066407
Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Derek J. Norris - Pennington NJ, US
Wen-Ching Han - Newtown PA, US
Gregory D. Vite - Titusville NJ, US
Brian E. Fink - West Windsor NJ, US
John S. Tokarski - Princeton NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A01N 43/42
A61K 31/44
C07D 487/00
C07D 491/00
C07D 513/00
US Classification:

514291, 540476
Abstract:

Disclosed are fused heterotricyclic compounds of the following formula I,.

Fused Tricyclic Compounds As Inhibitors Of 17Β-Hydroxysteroid Dehydrogenase 3
view source
US Patent:

7417040, Aug 26, 2008
Filed:

Feb 25, 2005
Appl. No.:

11/066373
Inventors:

Brian E. Fink - West Windsor NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Wen-Ching Han - Newtown PA, US
Raj N. Misra - Hopewell NJ, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 31/33
C07D 225/04
C07D 267/22
C07D 281/18
C07D 291/00
C07D 337/16
A01N 43/00
US Classification:

514183, 540466
Abstract:

Disclosed are fused tricyclic compounds of the following formula I,.